Sign In
Buy PEN
$319.37
+0.630 (+0.198%)
At Close: Jun 03, 2026
Penumbra, Inc. (PEN) Q4 2023 Earnings Call Transcript
08:55pm, Thursday, 22'nd Feb 2024
Penumbra, Inc. (PEN) Q4 2023 Earnings Call Transcript
Penumbra (PEN) Q4 Earnings Beat Estimates
06:41pm, Thursday, 22'nd Feb 2024
Penumbra (PEN) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.16 per share a year ago.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
08:15am, Tuesday, 20'th Feb 2024
Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Thursday, 15'th Feb 2024
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024
12:46pm, Tuesday, 26'th Dec 2023
Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.
Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?
11:18am, Friday, 22'nd Dec 2023
Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
12:02pm, Tuesday, 19'th Dec 2023
Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.
Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare Conference
07:50pm, Monday, 18'th Dec 2023
ALAMEDA, Calif. , Dec. 18, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P.
Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial
09:01am, Thursday, 30'th Nov 2023
Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
12:02pm, Tuesday, 14'th Nov 2023
Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.
Down -11.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Penumbra (PEN)
11:19am, Thursday, 09'th Nov 2023
Penumbra (PEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
10:33am, Friday, 03'rd Nov 2023
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.
Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript
09:33pm, Thursday, 02'nd Nov 2023
Penumbra, Inc. (PEN) Q3 2023 Earnings Call Transcript
Penumbra: Appeal Improves, Just Not Appealing Yet
12:03am, Monday, 16'th Oct 2023
Penumbra's shares have nearly been cut in half after doubling in a six-month period, making investors cautious. The company has shown continued growth since its IPO, with revenues increasing ten-fold
Here's Why You Should Hold on to Penumbra (PEN) Stock for Now
12:47pm, Thursday, 12'th Oct 2023
Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.
